Effectiveness and Cost-effectiveness of Thrombolysis in Submassive Pulmonary Embolism
Authors:
- Gillian D. SandersGSGillian D. Sanders
- Michael K. GouldMGMichael K. Gould
Open Access
- 8 January 2007
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 167 (1) , 74-80
Abstract
The role of thrombolytic therapy in acute pulmonary embolism has long been debated.1-3 Compared with heparin sodium alone, the addition of thrombolytic therapy improves hemodynamic and scintigraphic outcomes within 24 hours of administration, but these benefits diminish over time.4-7 For patients with pulmonary embolism and arterial hypotension, thrombolysis is considered to be the standard of care because prognosis in this group is so poor without thrombolytic therapy that the potential benefits are thought to far outweigh the risks.4,7-10 The controversy centers on treatment of hemodynamically stable patients with pulmonary embolism, especially those with right ventricular dysfunction. Right ventricular dysfunction is thought to be a sign of possible impending hemodynamic instability.1 It is present in 40% to 50% of patients with pulmonary embolism who are hemodynamically stable at the time of presentation, and right heart failure is a common cause of death in these patients.4,9,11,12 Patients with submassive pulmonary embolism and right ventricular dysfunction have mortality rates that are 2 times higher than those with normal right ventricular function.9,11,13Keywords
This publication has 1 reference indexed in Scilit:
- A Comparison of Reteplase with Alteplase for Acute Myocardial InfarctionNew England Journal of Medicine, 1997